View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 28, 2021updated 12 Jul 2022 11:13am

CStone’s sugemalimab meets primary goal in Phase III NSCLC trial 

CStone to seek new drug approval from the Chinese drug regulator for sugemalimab in stage III NSCLC indication.

CStone Pharmaceuticals has reported that its sugemalimab met the primary goal of improving progression-free survival (PFS) in a Phase III GEMSTONE-301 clinical study conducted on patients with stage III non-small-cell lung cancer (NSCLC).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Sugemalimab is an investigational anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody. It mimics the natural G-type immunoglobulin 4 human antibody, which lowers immunogenicity and possible toxicity risks.

The multi-centre, randomised, double-blind Phase III GEMSTONE-301 trial assessed the efficacy and safety of sugemalimab as consolidation therapy in locally advanced/unresectable stage III NSCLC subjects who had no disease progression on receiving concurrent or sequential chemoradiotherapy.

The secondary goals of the trial included safety profile, overall survival, and PFS as evaluated by investigators.

The latest interim analysis data demonstrated that subjects receiving sugemalimab had a statistically significant and clinically meaningful increase in PFS.

In addition, the investigator evaluated PFS was in line with the primary endpoint data.

The antibody was found to be well-tolerated in the trial, with no new safety signals noted.

Sugemalimab offered clinical benefit irrespective of whether patients received concurrent or sequential chemoradiotherapy before the antibody treatment, subgroup analyses showed.

CStone Pharmaceuticals chairman and CEO Dr Frank Jiang said: “We are excited that sugemalimab becomes the first anti-PD-1/PD-L1 monoclonal antibody in the world to cover both stage III and stage IV NSCLC patients.

“We are working closely with Pfizer and EQRx, our commercial partners for sugemalimab, on the next steps in our joint efforts to deliver this best-in-class drug to patients worldwide.”

The company intends to submit a new drug application (NDA) to the Chinese drug regulator National Medical Products Administration for sugemalimab in stage III NSCLC indication.

CStone along with EQRx will have discussions on stage III and stage IV NSCLC indications with various regulators, which includes the US Food and Drug Administration.

In October last year, CStone completed the previously announced share subscription agreement through which a Pfizer affiliate subscribed for newly issued CStone shares at around $200m.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena